Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-7240/PRA023 in systemic sclerosis-associated interstitial lung disease
NL-OMON53698Phase 2Not yet recruiting
- Sponsor
- Prometheus Biosciences
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD) and systemic sclerosis (SSc) comparing MK-7240/PRA023 with Placebo (2 arms). Primary endpoints: Safety and tolerability and Annual rate of change in forced vital capacity. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
tulisokibart
03
Conditions
pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD)systemic sclerosis (SSc)
Beyond the preview
Go deeper on NL-OMON53698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53698.